LSE:DNL (Diurnal Group Plc)
About DNL
Diurnal is an innovative pharmaceutical company that creates high-value therapeutics using advanced proprietary formulations and novel physiological treatment regimes of approved drugs for use in the endocrine (hormone) area. Founded in 2004, Diurnal is headquartered in Cardiff, United Kingdom, and is a specialty pharma company developing hormone therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
Financial Market Data copyright © 2025
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Profiles by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Financials by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2025
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Share Information by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Dividends by EDI/Mergent (USA) and TSX (CDN).
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Earnings and Analyst Ratings by Zacks.
Earnings Events by Wall Street Horizon.
Terms of Use.
Should you invest £1,000 in Centralnic Group Plc right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Centralnic Group Plc made the list?
Diurnal Group Plc (LSE: DNL) Latest News
Investing Articles
2 top pharma stocks I’d buy right now
